AI-driven drug discovery model sets new accuracy prediction benchmark
Iambic Therapeutics, an Nvidia-backed biotech based in London, have stated that their AI drug discovery model named ‘Enchant’ demonstrates the potential to reduce the time and cost associated with new drug development.
With training from large sets of preclinical data derived from laboratory tests, Enchant has been designed to predict how a given active molecule will perform in early development. A Whitepaper published by Iambic stated that Enchant demonstrated high accuracy in predictions concerning the absorption of new drugs in the human body when cross-referenced with real-world trials and outcomes; earlier models have previously achieved an accuracy prediction score of 0.58, while Enchant has demonstrated a 0.74 accuracy prediction score. This achievement comes as part of Iambic’s investment in developing new pharmaceuticals, and could potentially accelerate the new drug development pipeline at the earliest stage of development.
Co-Founder and CTO of Iambic Fred Manby commented to Reuters, “The cost of getting a product to market is often quoted at around USD$2 billion, and a lot of that isn’t about the programme costs but the failure rates. The costs of getting a product all the way to a marketed medicine derive from a high chance of late-stage failure. If you make a 10% improvement in each stage of clinical development, you would basically halve the cost because it applies cumulatively.”
Previous AI-driven programmes have also sought to advance the use of AI in drug discovery. For example, The Google DeepMind AlphaFold program that recently won the Nobel Prize in chemistry looked at predicting 3D strucutres of molecules binding with protein targets. However, 2018 Nobel Laureate and Iambic board member Frances Arnold says that is not enough. “The success of a drug candidate is determined by its pharmacokinetic, efficacy, and toxicity properties. Enchant addresses these distinct and important challenges,” he stated.
Source:
Nvidia-backed AI firm Iambic unveils drug discovery ‘breakthrough’ [Accessed November 11, 2024] https://www.reuters.com./technology/artificial-intelligence/nvidia-backed-ai-firm-iambic-unveils-drug-discovery-breakthrough-2024-10-29/
Related News
-
News Biopharmaceutical manufacturing boost part of new UK government budget
In their national budget announced by the UK Labour Party, biopharmaceutical production and manufacturing are set to receive a significant boost in capital grants through the Life Sciences Innovative Manufacturing Fund (LSIMF). -
News Women in Pharma: Moving beyond discussions and into best practice at CPHI Milan
In this second CPHI Milan special of our monthly series, we cover the key takeaways from the Diversity & Wellbeing track held on October 10, 2024. -
News AstraZeneca invests in AI collaboration for cancer drug trials
The British-Swedish pharmaceutical giant is partnering with biotechnology firm Immunai Inc to increase the efficiency of some cancer drug trials. -
News Ozempic and Wegovy prices questioned as Novo Nordisk faces US Senate hearing
The CEO of Novo Nordisk was grilled during a US Senate committee hearing on September 24, 2024, in which the exorbitant prices of the Danish company’s blockbuster drugs Ozempic and Wegovy were called into question. -
News The BIOSECURE Act: implications for the pharma supply chain
On September 9, 2024, the US House of Representatives voted to pass the bill titled the BIOSECURE Act (the Act), which lists several Chinese companies in the pharmaceutical supply chain. The Act will prohibit American companies from contracting or doin... -
News On Track at CPHI Milan: Thermo Fisher Scientific Track Sponsor interview
With CPHI Milan just around the corner, we sat down with some of the sponsors for this year’s conference tracks to discuss the most pressing topics in pharma. -
News CPHI Milan Speaker Spotlight: Pharma Manufacturing and Localisation in Africa
In the run-up to CPHI Milan, we sit down with some of the experts and thought-leaders speaking at this year’s conferences. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance